The Glucose Monitor That Just Skipped the Doctor's Office

Stelo sidesteps the whole system. It's a cash-pay, over-the-counter product. Walk into a store, buy it, put it on your kid. That's the kind of simplicity that could pull in families who were never going to jump through the traditional hoops.

The Business Angle: Small Sensor, Big Market

Dexcom isn't doing this out of pure altruism. The company is on a tear, guiding 2026 revenue to $5.18–$5.25 billion after posting 12% year-over-year growth in Q1 and 15% in Q2. Stelo is the tip of a strategic spear aimed at a massive, undertapped population: the millions of people (and now kids) managing glucose without insulin.

The OTC CGM market is still a two-horse race between Dexcom and Abbott, whose FreeStyle Libre franchise dominates overall CGM share. But neither Abbott nor any other competitor has an OTC CGM cleared for pediatric use, which gives Dexcom a head start in a brand-new lane.

Analysts have been mostly upbeat. When Dexcom raised its full-year guidance, the $5.215 billion midpoint came in just a hair below the Street's $5.24 billion consensus; not a blowout, but enough to signal that Stelo's commercial rollout is tracking. The company also announced a revamped Stelo app and plans for international expansion later in 2026 and into 2027.

Not Everyone Is Cheering

The FDA framed the approval as a win for "fostering innovation for pediatric patients" and supporting kids in the settings where they "live, learn, and play." Hard to argue with that pitch.

But some voices in the pediatric and public health communities have raised legitimate questions. Strapping a biometric sensor on a toddler is qualitatively different from handing one to a 40-year-old. Concerns include clinical appropriateness for very young children, privacy implications of continuous health data collection, and the psychological impact of early biometric monitoring, especially if the device gets used beyond clear medical need.

There's also the "wellness creep" factor. Stelo's label explicitly covers kids who just want to understand how lifestyle factors affect glucose. That's a useful tool for a child with prediabetes. But it also opens the door to anxious parents monitoring perfectly healthy kids, turning every post-birthday-cake glucose spike into a crisis. The FDA noted that children should use the device under adult caregiver supervision, but that guardrail is only as strong as parental judgment.

The Bigger Picture: CGMs Go Mainstream

Zoom out and this approval fits a clear trend. CGMs are migrating from the endocrinologist's office to the pharmacy shelf, from insulin-dependent patients to the general population, and now from adults to kids. Companies like Levels, Nutrisense, and January AI have already built wellness platforms around OTC sensors, turning glucose tracking into something closer to step counting.

Dexcom's pediatric clearance accelerates that shift. If glucose monitoring becomes as routine as checking a kid's temperature, the total addressable market for CGMs expands dramatically. The competition isn't standing still, either; barriers to entry remain high thanks to FDA accuracy standards and regulatory requirements, but the prize is big enough to attract new players.

For now, Dexcom has a first-mover advantage in pediatric OTC monitoring and the resources to fund the push. The question isn't whether kids will wear CGMs. It's how quickly this becomes normal.

The Bottom Line

Dexcom just made it possible for any parent to buy a continuous glucose monitor for their child without asking a doctor first. That's a genuine milestone for access, a smart commercial bet on a growing market, and a development worth watching carefully. Because when you remove the prescription barrier for a pediatric health device, you're not just changing who monitors glucose. You're changing how an entire generation thinks about metabolic health.

The Flu Shot Just Got Its Biggest Upgrade in Decades

The FDA just approved the first-ever mRNA flu vaccine, and it beat traditional shots in a 41,000-person trial. Moderna's mFlusiva won't make much money this year, but it might reshape a $9 billion market.